Inhibition of placental growth factor in renal cell carcinoma.

Autor:	Bessho H; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan hideji56@gmail.com., Wong B; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Huang D; Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, MI, U.S.A., Siew EY; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Huang D; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Tan J; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Ong CK; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Tan SY; Department of Pathology, Singapore General Hospital, Singapore, Singapore., Matsumoto K; Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan., Iwamura M; Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan., Teh BT; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2015 Jan; Vol. 35 (1), pp. 531-41.
Abstrakt:	Background/aim: Placental growth factor (PlGF) is up-regulated in major malignant diseases or following antiangiogenic therapy, although it is present in low levels under normal physiological conditions. TB403, a monoclonal antibody against PlGF, was investigated in clear cell renal cell carcinoma (ccRCC) xenografts since it has been proposed as a potential target in oncology. Materials and Methods: Human ccRCCs were implanted in athymic nude mice to evaluate the efficacy of TB403 and to excise xenograft tumors for molecular experiments. Results: TB403 did not significantly inhibit tumor growth in treatment-naïve or sunitinib-resistant ccRCC xenografts. Gene expression profiling resulted in over-expression of the C1orf38 gene, which induced immunoreactivity in macrophages. Angiogenesis PCR arrays showed that VEGFR-1 was not expressed in ccRCC xenografts. Conclusion: PlGF blockade did not have a broad antiangiogenic efficacy; however, it might be effective on-target in VEGFR1-expressing tumors. The inhibition of VEGF pathway may induce the activity of tumor-associated-macrophages for angiogenesis escape. (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu